Skip to main content

Canadian Investor Grants Warnex Three Months to Repay $500K

NEW YORK (GenomeWeb News) – The genetic testing, molecular diagnostics, and lab services company Warnex said today it has been granted a waiver from an investor for the repayment of $500,000 it owes as a quarterly capital investment payment that was due today. 
 
Warnex said SIPAR, a Montreal-based investment company, has given it until April 1 to make this payment. Warnex also said the agreement is part of a strategy it announced last month to restructure its debts and reorganize its financing in order to stabilize its balance sheet.
 
Warnex CEO Mark Busgang said the agreement shows SIPAR’s “confidence in our ability to reorganize our financial instruments.”

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.